Association between plasma concentrations of galectin 3, growth differentiation factor 15, soluble suppression of tumourigenicity 2, and cystatin C and clinical parameters and survival in patients with end-stage renal disease undergoing haemodialysis
Open Access
- 13 March 2026
- journal article
- research article
- Published by Springer Nature in Amino Acids
- Vol. 58 (1)
Abstract
The treatment of chronic kidney disease is based mainly on haemodialysis. During this procedure, cardiovascular haemodynamic parameters change, which can lead to complications in the circulatory system and shorten patient survival. Currently, new biomarkers are being sought that could predict survival in haemodialysis patients. The aim of this study was to evaluate whether Gal-3, GDF-15, sST2, and CysC could be useful biomarkers in patients with end-stage renal failure undergoing haemodialysis in predicting the patient survival. This study included 76 patients with end-stage kidney disease treated with haemodialysis. We assessed the variability in the plasma concentrations of these proteins; evaluated correlations between Gal-3, GDF-15, and sST2 concentrations and selected haemodialysis parameters; and determined the relationship between the risk of death and Gal-3, GDF-15, sST2, and CysC concentrations. There was a decrease in the Gal-3 plasma concentrations and an increase in the GDF-15 and sST2 plasma concentrations during haemodialysis. Among the studied proteins, only the sST2 concentrations differed significantly between the patients who survived and died. The logarithm of the sST2 concentrations, both before and after haemodialysis, was an independent mortality risk factor in univariate analysis (respectively: hazard ratio [HR] 3.179, 95% confidence interval [CI] 1.492–6.777, p = 0.0027, and HR 3.011, 95% CI 1.447–6.264, p = 0.0032) and multivariate analysis, which also included age, male gender, and body mass index (respectively: HR 2.776, 95% CI 1.306–5.903, p = 0.0080, and HR 2.496, 95% CI 1.224–5.090, p = 0.012). These results suggest the use of sST2 in clinical practice to identify patients at higher risk of death.Keywords
This publication has 51 references indexed in Scilit:
- Predicting Contrast-induced Renal ComplicationsInterventional Cardiology Clinics, 2023
- Potential biomarkers for early detection of diabetic kidney diseaseDiabetes Research and Clinical Practice, 2020
- Independent and incremental prognostic value of novel cardiac biomarkers in chronic hemodialysis patientsAmerican Heart Journal, 2016
- KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 UpdateAmerican Journal of Kidney Diseases, 2015
- Plasma concentrations of novel cardiac biomarkers before and after hemodialysis sessionClinical Biochemistry, 2015
- Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk StratificationJACC, 2014
- Measurement of the Interleukin Family Member ST2 in Patients With Acute DyspneaJACC, 2007
- Acute Renal Failure and Renal Support2007
- Expression of a novel member of the TGF-β superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissuesCell and tissue research, 1999
- Identification of a novel member of the TGF-beta superfamily highly expressed in human placentaGene, 1997